title: Intraperitoneal Administration of Low Dose Aluminium in The Rat: How Good is It to Produce a Model for Alzheimer Disease.
abstract: Since neurotoxicity of aluminium (Al) resembles the progressive neurodegeneration observed in Alzheimer Disease (AD), Al administration in several ways has been used to produce AD model. Intraperitoneal (ip) low dose (4.2 mg/ kg) Al injection in rats for long periods is the preferred method by some researchers. In this paper, the efficiency of this method for producing an AD model was evaluated. In this study, we looked at the neuropathology of Al and the characteristic lesions of AD by histological and immunohistochemical techniques and determined oxidative stress markers in the brains of Al-treated and control rats. We also made electrophysiological recordings at the hippocampus and evaluated possible behavioural changes by Morris water maze test. However, no pathologic changes occurred in the animals except for an impairment in long-term potentiation (LTP) in the hippocampus (e.g. the LTPs of population spike (PS) amplitude at 15 min post-tetanus were measured as 217±27% in Al-treated rats and as 240±42% in sham-treated rats, of baseline PS amplitude). According to the findings of the present study, low dose of ip Al in rats is not sufficient to produce a good AD model. Higher doses (≥10 mg/kg) should be used.
authors.affiliation: Erciyes University. basriulusoy@gmail.com.
authors.forename: H B
authors.initials: HB
authors.lastname: Ulusoy
authors.forename: M F
authors.initials: MF
authors.lastname: Sonmez
authors.forename: E
authors.initials: E
authors.lastname: Kilic
authors.forename: K
authors.initials: K
authors.lastname: Caliskan
authors.forename: B
authors.initials: B
authors.lastname: Karaca
authors.forename: M
authors.initials: M
authors.lastname: Kara
authors.forename: O
authors.initials: O
authors.lastname: Ercal
authors.forename: Y
authors.initials: Y
authors.lastname: Gunduz
authors.forename: D
authors.initials: D
authors.lastname: Karabulut
authors.forename: S
authors.initials: S
authors.lastname: Bitiktas
authors.forename: B
authors.initials: B
authors.lastname: Tan
authors.forename: S
authors.initials: S
authors.lastname: Kavraal
authors.forename: A
authors.initials: A
authors.lastname: İnal
authors.forename: C
authors.initials: C
authors.lastname: Suer
mesh_terms: D000535:Aluminum / Q000008:administration & dosage / Q000378:metabolism; D000544:Alzheimer Disease / Q000139:chemically induced*; D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D055724:Electrophysiological Phenomena / Q000187:drug effects; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D005260:Female; D006624:Hippocampus / Q000187:drug effects; D007150:Immunohistochemistry; D007274:Injections, Intraperitoneal; D017774:Long-Term Potentiation / Q000187:drug effects; D018782:Maze Learning / Q000187:drug effects; D018384:Oxidative Stress; D051381:Rats; D017208:Rats, Wistar; D013438:Sulfhydryl Compounds / Q000378:metabolism; D014969:Xanthine Oxidase / Q000378:metabolism
chemical_list: D013438:Sulfhydryl Compounds; D000535:Aluminum; D014969:Xanthine Oxidase